A Phase 1 interventional study of Trazodone HCl and Trazodone HCl in Healthy Subjects, Bioavailability and Pharmacokinetics, sponsored by Labopharm Inc.. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-04-30.
Sponsored by Labopharm Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to compare the pharmacokinetic profiles at steady state of the test product, 300 mg trazodone hydrochloride (HCl) extended-release caplets (containing Contramid®), when administered once daily, and the reference product, 100 mg trazodone HCl immediate-release tablets (Apotex Corp.), when administered three times daily, for one week. For this purpose, the rate and extent of absorption of trazodone and formation of m-chlorophenylpiperazine (mCPP) after administration of multiple doses of up to 300 mg of each of the two formulations was compared.
Labopharm Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For females, the following conditions had to be met:
was of , and all of the following conditions were met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OAD: Once A Day
Drug: Trazodone HCl
Drug: Trazodone HCl
Dosage form: Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study). Dose regimen: 75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours.
Also known as: Oleptro
Dosage form: Immediate-release tablet containing 100 mg trazodone HCl Dose regimen: 100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours.
Bioequivalence Based on Cmax,ss
Cmax,ss = Maximum plasma concentration (Cmax) at steady state (ss): (Cmax,ss). Measured in nanograms per milliliter (ng/mL).
Time frame: 9 days
Bioequivalence Based on AUCss
AUCss = Area under the plasma concentration curve (AUC) vs. time data pairs at steady state (ss): AUCss. Measured in nanograms x hours per milliliter (ng\*h/mL).
Time frame: 9 days
Minimum Plasma Concentration (Cmin,ss)
Minimum plasma concentration at steady state (Cmin,ss). Measured in nanograms per milliliter (ng/mL)
Time frame: 9 days
Plasma Concentration at 24 Hours Post-evening Dose (C24h)
Plasma concentration at 24 hours post-evening dose (C24h) in nanograms per milliliter (ng/mL)
Time frame: 9 days
Time to Peak Exposure (Tmax)
Time to peak exposure (Tmax) at steady state.
Time frame: 9 days
Percentage Swing
Percentage swing is a pharmacokinetic parameter calculated as follows: ((Cmax,ss - Cmin,ss)/Cmin,ss)\*100. Where: Cmax,ss = Maximum concentration at steady state; Cmin,ss = Minimum concentration at steady state. It was calculated over 24 hours on day 9.
Time frame: 9 days
Percentage Peak-Trough Fluctuation (%PTF)
Percentage Peak-Trough Fluctuation (%PTF) of trazodone calculated as \[100\*(Cmax-Cmin)/Cav\]. Cmax: Maximum plasma concentration Cmin: Minimum plasma concentration Cav: Average plasma concentration
Time frame: 9 days
| Milestone | Test (Trazodone Contramid® OAD) First | Reference (Trazodone IR [Apotex Corp.]) First |
|---|---|---|
| Started | 15 | 15 |
| Completed | 14 | 15 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Test (Trazodone Contramid® OAD) First | Reference (Trazodone IR [Apotex Corp.]) First |
|---|---|---|
| Started | 14 | 15 |
| Completed | 14 | 13 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Positive pregnancy test | 0 | 1 |
| Milestone | Test (Trazodone Contramid® OAD) First | Reference (Trazodone IR [Apotex Corp.]) First |
|---|---|---|
| Started | 14 | 13 |
| Completed | 14 | 13 |
| Not completed | 0 | 0 |
Cmax,ss = Maximum plasma concentration (Cmax) at steady state (ss): (Cmax,ss). Measured in nanograms per milliliter (ng/mL).
| ng/mL | Trazodone Contramid® OAD | Trazodone HCl (Apotex Corp.) |
|---|---|---|
| Bioequivalence Based on Cmax,ss | 1812.026 ± 620.625 | 3117.778 ± 757.508 |
AUCss = Area under the plasma concentration curve (AUC) vs. time data pairs at steady state (ss): AUCss. Measured in nanograms x hours per milliliter (ng\*h/mL).
| ng*h/mL | Trazodone Contramid® OAD | Trazodone HCl (Apotex Corp.) |
|---|---|---|
| Bioequivalence Based on AUCss | 29131.374 ± 9930.767 | 33058.024 ± 8006.118 |
Minimum plasma concentration at steady state (Cmin,ss). Measured in nanograms per milliliter (ng/mL)
| ng/mL | Trazodone Contramid® OAD | Trazodone HCl (Apotex Corp.) |
|---|---|---|
| Minimum Plasma Concentration (Cmin,ss) | 673.889 ± 354.647 | 842.763 ± 273.592 |
Plasma concentration at 24 hours post-evening dose (C24h) in nanograms per milliliter (ng/mL)
| ng/mL | Trazodone Contramid® OAD | Trazodone HCl (Apotex Corp.) |
|---|---|---|
| Plasma Concentration at 24 Hours Post-evening Dose (C24h) | 747.270 ± 329.025 | 919.111 ± 289.382 |
Time to peak exposure (Tmax) at steady state.
| hours | Trazodone Contramid® OAD | Trazodone HCl (Apotex Corp.) |
|---|---|---|
| Time to Peak Exposure (Tmax) | 8.00 (3.00 to 16.0) | 8.33 (8.33 to 19.0) |
Percentage swing is a pharmacokinetic parameter calculated as follows: ((Cmax,ss - Cmin,ss)/Cmin,ss)\*100. Where: Cmax,ss = Maximum concentration at steady state; Cmin,ss = Minimum concentration at steady state. It was calculated over 24 hours on day 9.
| Percentage swing | Trazodone Contramid® OAD | Trazodone HCl (Apotex Corp.) |
|---|---|---|
| Percentage Swing | 210.769 ± 127.806 | 302.805 ± 144.467 |
Percentage Peak-Trough Fluctuation (%PTF) of trazodone calculated as \[100\*(Cmax-Cmin)/Cav\]. Cmax: Maximum plasma concentration Cmin: Minimum plasma concentration Cav: Average plasma concentration
| Percentage Peak-Trough Fluctuation | Trazodone Contramid® OAD | Trazodone HCl (Apotex Corp.) |
|---|---|---|
| Percentage Peak-Trough Fluctuation (%PTF) | 97.090 ± 28.357 | 174.768 ± 69.648 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trazodone Contramid® OAD | — | 0/28 (0%) | 11/28 (39.3%) |
| Trazodone HCl (Apotex Corp.) | — | 0/29 (0%) | 13/29 (44.8%) |
| Event | Trazodone Contramid® OAD | Trazodone HCl (Apotex Corp.) |
|---|---|---|
| HeadacheNervous system disorders | 5/28 | 3/29 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 4/28 | 1/29 |
| DizzinessNervous system disorders | 2/28 | 4/29 |
| Dry mouthGastrointestinal disorders | 3/28 | 1/29 |
| NauseaGastrointestinal disorders | 2/28 | 2/29 |
| ConstipationGastrointestinal disorders | 2/28 | 1/29 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/28 | 2/29 |
| InsomniaPsychiatric disorders | 0/28 | 2/29 |
| Age, Categorical(Participants) | Entire Study Population |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 30 |
| >=65 years | 0 |
| Age Continuous(years) | Entire Study Population |
|---|---|
| Mean | 25.7 ± 8.4 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 9 |
| Male | 21 |
| Region of Enrollment(participants) | Entire Study Population |
|---|---|
| South Africa | 30 |
No study locations are listed for this record.
The record gives a start of Jan 2008, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trazodone
Labopharm Inc.